|
Jul 2
|
Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors
|
|
Jun 20
|
Instil Bio, Inc. (TIL) Is Up 4.07% in One Week: What You Should Know
|
|
Jun 16
|
Wall Street Analysts Think Instil Bio (TIL) Could Surge 246.68%: Read This Before Placing a Bet
|
|
May 23
|
Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in Chicago
|
|
May 22
|
Instil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 (‘2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in China is on Track to Complete Enrollment in Q3 2025; Initial Results Anticipate...
|
|
May 13
|
Instil Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update
|
|
Feb 20
|
Private equity firms who hold 38% of Instil Bio, Inc. (NASDAQ:TIL) gained 34%, institutions profited as well
|
|
May 10
|
Instil Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
|
|
Mar 27
|
What Makes Instil Bio (TIL) a New Buy Stock
|
|
Mar 21
|
Instil Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
|
|
Jan 16
|
Instil Bio Announces Strategic Update
|
|
Dec 5
|
Instil Bio Announces Effective Date of 1-for-20 Reverse Stock Split
|